Senolytic peptides and cellular senescence: targeted clearance of ageing cells

Cellular senescence is an evolutionarily conserved stress response: damaged cells that cannot safely divide arrest permanently rather than risking replication of defective DNA. In the short term, senescence serves protective functions — in wound healing, tumour suppression, and embryonic development. In the long term, the accumulation of senescent cells in tissues drives chronic inflammation, stem cell exhaustion, and progressive functional decline.

The senolytic research field aims to selectively clear senescent cells from tissues, either reversing or slowing age-related pathology. Peptide-based approaches represent one mechanistically distinct arm of this field, with advantages including tuneability, reduced off-target toxicity, and potential for cell-type-specific targeting.

The biology of cellular senescence

Senescent cells enter their arrested state through converging pathways involving activation of the p53/p21 or p16^INK4a/Rb tumour suppressor axes. Once arrested, they adopt the senescence-associated secretory phenotype (SASP) — characterised by elevated secretion of pro-inflammatory cytokines (IL-6, IL-8), matrix metalloproteinases (MMPs), and growth factors.

The SASP creates a local inflammatory microenvironment with systemic consequences. In aged tissues, where senescent cell burden is higher, the cumulative SASP drives "inflammaging" — the chronic low-grade inflammation associated with multiple age-related diseases including atherosclerosis, type 2 diabetes, neurodegeneration, and cancer.

Critically, senescent cells resist apoptosis through upregulation of pro-survival pathways, including BCL-2 family anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W), PI3K/Akt signalling, and serpine 1 (PAI-1). These survival mechanisms are the primary therapeutic targets for senolytic interventions.

Senescent cell identification

Reliable identification of senescent cells remains methodologically important for interpreting research findings. Key markers include:

• p16^INK4a expression: Drives Rb-mediated cell cycle arrest; validated marker for senescent burden in aged tissues
• Senescence-associated beta-galactosidase (SA-β-Gal): Elevated lysosomal activity detectable at pH 6.0; widely used histological marker
• γ-H2AX foci: Persistent DNA damage response activation characteristic of senescent cells
• SASP factor elevation: Multiplex cytokine measurement (IL-6, IL-8, MMP-3) provides functional readout

FOXO4-DRI: the best-characterised peptide senolytic

The most studied peptide senolytic is FOXO4-DRI, developed by van Deursen and colleagues (Baar et al., Cell, 2017). The approach exploits a survival interaction specific to senescent cells: in these cells, FOXO4 (a forkhead transcription factor) retains p53 in the nucleus, preventing p53-mediated apoptosis despite the cell harbouring severe DNA damage.

FOXO4-DRI is a D-amino acid retro-inverso peptide designed to penetrate cells and competitively disrupt the FOXO4–p53 interaction. Retro-inverso design (D-amino acids in reversed sequence) confers protease resistance while maintaining the binding geometry of the native L-amino acid peptide — a strategy also employed in other therapeutic peptide development to extend half-life.

In naturally aged mice, FOXO4-DRI administration:

• Reduced p16^INK4a-positive senescent cells across multiple tissues
• Improved physical fitness parameters including running endurance and grip strength
• Restored renal function in a chemotherapy-induced senescence model
• Reversed doxorubicin-induced alopecia (hair loss)
• Showed no apparent toxicity to non-senescent cells at effective doses

The cell-type selectivity was attributed to FOXO4's elevated nuclear localisation specifically in senescent cells — in non-senescent cells, FOXO4 is not required for survival, so disrupting its interaction with p53 has minimal effect on apoptotic threshold.

BCL-2 family-targeting peptides

Senescent cells' dependence on BCL-2 family anti-apoptotic proteins has motivated development of BH3 mimetic peptides — peptides mimicking the BH3 domain of pro-apoptotic BCL-2 family members that normally bind and inhibit the anti-apoptotic proteins.

BH3 mimetic peptides sensitise senescent cells to apoptosis by occupying the hydrophobic groove of BCL-2/BCL-XL, releasing sequestered pro-apoptotic effectors (BAX, BAK) and initiating mitochondrial outer membrane permeabilisation.

The challenge is selectivity: non-senescent cells that depend on BCL-2 family proteins for survival (including neurons and platelets) are also vulnerable. Research has focused on preferentially targeting BCL-XL (which shows greater upregulation in senescent cells versus BCL-2's broader expression) and on cell-penetrating carrier peptides that accumulate in cells with elevated SA-β-Gal activity — exploiting the biophysical properties of senescent cells' enlarged lysosomes as a targeting handle.

GLS1 inhibition and lysosomal targeting

Senescent cells show elevated glutaminase 1 (GLS1) activity, required for amino acid synthesis supporting the metabolically demanding SASP. Peptide inhibitors targeting GLS1, delivered via lysosome-accumulating carrier systems that preferentially concentrate in SA-β-Gal-high cells, represent an emerging approach with preclinical data showing senescent cell reduction without detectable non-senescent cell toxicity.

This lysosome-targeted delivery strategy is notable for its mechanism of tissue selectivity — it exploits a physical property of senescent cells (enlarged lysosomes with altered pH) rather than a surface receptor, potentially making it less susceptible to target downregulation.

Senostatics: SASP suppression without clearance

Distinct from senolytics (which clear senescent cells), senostatics suppress SASP secretion while leaving senescent cells in place. Peptide-based senostatic approaches target key SASP regulatory nodes:

NF-κB pathway peptides: Cell-penetrating peptides inhibiting IKKβ reduce IL-6 and IL-8 secretion from senescent cells. NF-κB is the central transcription factor driving SASP cytokine expression, making it a high-leverage senostatic target.

mTORC1 inhibitory peptides: mTORC1 is required for translation of SASP factor mRNAs; allosteric mTORC1-inhibitory peptides reduce SASP output without the immune suppression associated with broad PI3K inhibition.

cGAS-STING pathway inhibition: Cyclic GMP-AMP synthase (cGAS) detects cytoplasmic DNA from dysfunctional nuclei in senescent cells, activating interferon responses that constitute the innate immune component of SASP. Peptide inhibitors of this pathway reduce the interferon-driven SASP elements that contribute most to paracrine senescence spread.

Clinical translation challenges

Delivery: Achieving sufficient tissue concentrations via systemic administration while avoiding off-target effects in sensitive tissues (bone marrow, gut epithelium) remains a key challenge.

Selectivity verification: Confirming in vivo selectivity for senescent cells — particularly avoiding depletion of post-mitotic cells with constitutively high anti-apoptotic protein expression — requires robust biomarker readouts not yet validated in human trials.

Intermittent dosing: The "hit-and-run" dosing strategies used in animal studies (where drug clears before next dose) may not translate directly to human pharmacokinetics given species differences in drug half-life and senescent cell clearance rates.

Tissue heterogeneity: Different tissues harbour senescent cells with different molecular profiles and survival dependencies; tissue-specific senolytic strategies may be required rather than universal approaches.

Connections to longevity research

Selective clearance of p16^INK4a-positive cells in transgenic mouse models has extended median lifespan and compressed morbidity, demonstrating that senescent cell accumulation is a causal contributor to ageing rather than merely a biomarker. This connects to the broader longevity research framework examined in our epigenetic clocks and peptide interventions article.

The SASP's relationship to systemic inflammaging also intersects with NAD+ biology and sirtuin signalling, since sirtuins regulate both SASP gene expression and the DNA damage response driving cells into senescence in the first place.

Summary

Cellular senescence contributes to tissue ageing through SASP-driven inflammation and impaired homeostasis. Peptide-based senolytic strategies — including FOXO4-DRI, BH3 mimetics, lysosome-targeted GLS1 inhibitors, and SASP-suppressing senostatics — offer mechanistically distinct tools for addressing senescent cell burden. FOXO4-DRI remains the most characterised peptide senolytic with in vivo efficacy data in aged mice. Translation to humans faces delivery, selectivity verification, and biomarker challenges, though the field is advancing rapidly toward first-in-human studies.